Eloxx Pharmaceuticals is a biopharmaceutical company developing small-molecule therapies for rare genetic diseases affecting the kidneys and skin, with exaluren as its lead candidate targeting premature termination codons across multiple rare genetic indications. The company maintains a portfolio of product candidates in preclinical and clinical development stages, pursuing growth through internal research programs and strategic collaborations, including in-licensing opportunities and potential mergers and acquisitions. Eloxx generates value through its intellectual property, including licensed technology from academic institutions and patent protections on its lead candidate, while facing the typical challenges of rare-disease biopharmaceutical development including regulatory approval requirements, restricted commercialization to approved indications, and reimbursement pressures across jurisdictions.